• Precursor B-cell lymphoblastic leukemia is a form of lymphoid leukemia in which too many B-cell lymphoblasts (immature white blood cells) are found in the blood and bone marrow. (wikipedia.org)
  • A malignancy in the lymphoid lineage that includes white blood cells such as T lymphocytes and B lymphocytes. (medgadget.com)
  • Acute lymphoblastic leukemia (acute lymphocytic leukemia, ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. (medscape.com)
  • The malignant cells of ALL are lymphoid precursor cells (ie, lymphoblasts) that are arrested in an early stage of development. (medscape.com)
  • Virtually absent from normal pediatric and adult tissues, with the exception of low-level expression in a subset of immature b cell precursors known as hematogones and adipocytes, ROR1 is notably overexpressed, and considered a survival factor, in a number of B lymphoid and epithelial malignancies: including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), marginal zone lymphoma, lung adenocarcinoma. (peprotech.com)
  • A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. (lookformedical.com)
  • The 2016 World Health Organization (WHO) classification of lymphoid neoplasms incorporates genetic data, clinical features, cell morphology, and immunophenotype, all of which have important implications for disease prognosis and management. (msdmanuals.com)
  • While more than half of patients with AML go into remission after treatment with chemotherapy, many relapse due to residual leukemia cells evading both chemotherapy and the immune system. (pharmacytimes.com)
  • Scholars@Duke publication: Sex-Specific Associations Between Chemotherapy, Chronic Conditions, and Neurocognitive Impairment in Acute Lymphoblastic Leukemia Survivors: A Report From the Childhood Cancer Survivor Study. (duke.edu)
  • BACKGROUND: The purpose was to examine associations between treatment and chronic health conditions with neurocognitive impairment survivors of acute lymphoblastic leukemia (ALL) treated with chemotherapy only. (duke.edu)
  • We will establish two prospective groups of patients with Acute Lymphoclastic Leukemia (ALL): "Cohort A" will be enrolled on the study at the time of diagnosis while "Cohort B" will be enrolled during maintenance chemotherapy. (rochester.edu)
  • The genomic MLL-MLLT3 (MLL-AF9) fusion site was amplified by a multiplex, nested long-range PCR and used as a clonal marker for quantification of the MLL-MLLT3-positive cells during chemotherapy. (uni-luebeck.de)
  • Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. (unimib.it)
  • Purpose: To assess the effect of treatment intensification and that of extended intrathecal methotrexate substitution for cranial irradiation in intermediate-risk acute lymphoblastic leukemia (ALL) children treated with a Berlin-Frankfurt-Munster (BFM)-based intensive chemotherapy. (unimib.it)
  • Treatment typically includes combination chemotherapy to achieve remission, intrathecal and systemic chemotherapy and/or corticosteroids for CNS prophylaxis, and sometimes cerebral irradiation for intracerebral leukemic infiltration, consolidation chemotherapy with or without stem cell transplantation, and maintenance chemotherapy for up to 3 years to avoid relapse. (msdmanuals.com)
  • Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. (nih.gov)
  • Acute lymphoblastic leukaemia (ALL) is rare under 1 year and has a poor prognosis. (nih.gov)
  • This retrospective study was carried out in 66 children ranging from 1 « years to 12 « years who were referred to Cancer Institute, Maharagama, Sri Lanka after being diagnosed as having Acute Lymphoblastic Leukaemia. (who.int)
  • The treatment given had been the standard treatment for Acute lymphoblastic leukaemia during the period concerned. (who.int)
  • SIRIWARDENA, PAV, Acute lymphoblastic leukaemia in Sri Lankan children: a 10 year experience at National Cancer Institute, Sri Lanka, Post Graduate Institute of Medicine, Colombo PGIM , 1995: 31p. (who.int)
  • TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia. (cancercentrum.se)
  • The spectrum of acute central nervous system symptoms during the treatment of childhood acute lymphoblastic leukaemia. (cancercentrum.se)
  • Within the B-cell and T-cell categories, two subdivisions are recognized: precursor neoplasms, which correspond to the earliest stages of differentiation, and more mature differentiated neoplasms. (medscape.com)
  • KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. (rochester.edu)
  • Brexucabtagene autoleucel (Tecartus - Kite) has been approved by the FDA for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). (medletter.com)
  • It was previously approved for treatment of relapsed or refractory mantle cell lymphoma. (medletter.com)
  • The CAR T-cell immunotherapy tisagenlecleucel (Kymriah) was approved in 2017 for treatment of relapsed or refractory B-cell precursor ALL in patients ≤25 years old. (medletter.com)
  • Tisagenlecleucel is approved for patients up to 25 years of age with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) and for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. (ascopost.com)
  • A. Cytokine-release syndrome was observed in 40% to 50% of pediatric and young adult patients with relapsed or refractory ALL and adult patients with relapsed or refractory large B-cell lymphomas. (ascopost.com)
  • Gilead's Yescarta (axicabtagene ciloleucel), at $373,000, is approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. (managedhealthcareexecutive.com)
  • T-cell/histiocyte-rich large B-cell lymphoma - a distinct clinicopathologic entity or a variant of diffuse large B cell lymphoma? (llu.edu)
  • SERT was readily detected in derived B cell lines with origins as diverse as B cell precursor acute lymphoblastic leukemia, mantle cell lymphoma, diffuse large B cell lymphoma, and multiple myeloma. (erowid.org)
  • The FDA has approved lisocabtagene maraleucel (Breyanzi - BMS) for treatment of adults with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise. (medletter.com)
  • The CAR T-cell products axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) are also FDA-approved for treatment of large B-cell lymphoma. (medletter.com)
  • These phrases were contained in old descriptors which now are subsumed under NON-HODGKINS LYMPHOMA or FOLLICULAR LYMPHOMA. (bvsalud.org)
  • The diagnosis and differential diagnosis of 'small' B cell lymphomas. (llu.edu)
  • Acute Leukemia Diagnosis - A Practical Morphologic, Immunophenotypic, and Cytogenetic Approach. (llu.edu)
  • See the Childhood Acute Lymphoblastic Leukemia: Diagnosis, Management, and Complications slideshow to help recognize and treat this disease and its associated complications. (medscape.com)
  • Which statement about the diagnosis and management of cytokine-release syndrome after CAR T-cell infusion is correct? (ascopost.com)
  • A quarter of all extranodal lymphomas occur in the head and neck, and 8% of findings on supraclavicular fine-needle aspirate biopsy yield a diagnosis of lymphoma. (medscape.com)
  • Many of the leukemia terms have undergone name changes as immunophenotypic and molecular biological techniques have made diagnosis more precise. (bvsalud.org)
  • Symptoms and signs of acute lymphoblastic leukemia may be present for only days to weeks before diagnosis. (msdmanuals.com)
  • ALL is the most prevalent childhood malignancy, with precursor B-cell ALL (B-ALL) accounting for approximately 75-80% of newly diagnosed pediatric ALL cases. (wikipedia.org)
  • OBJECTIVES: I. Assess the feasibility and outcome of intensified induction/consolidation followed by intensified re-induction/re-intensification in infants less than 1 year of age with newly diagnosed acute lymphocytic leukemia (ALL). (knowcancer.com)
  • BOSULIF (bosutinib) has been granted a positive opinion for the treatment of adults with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). (medgadget.com)
  • Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. (ucdenver.edu)
  • American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. (rochester.edu)
  • Acute lymphoblastic leukemia (ALL) is the commonest childhood malignancy and is characterized by recurring structural genetic alterations. (lu.se)
  • And, malignancy in the myeloid lineage that includes precursor cells to red blood cells, platelets and white blood cells such as granulocytes. (medgadget.com)
  • Following our previous description of the serotonin transporter (SERT) acting as a conduit to 5-hydroxytryptamine (5-HT)-mediated apoptosis, specifically in Burkitt's lymphoma, we now detail its expression among a broad spectrum of B cell malignancy, while exploring additional SERT substrates for potential therapeutic activity. (erowid.org)
  • Introduction: Myeloid/Natural killer (NK) cell precursor acute leukemia (MNKPL) is a rare hematologic malignancy prevalent in East Asia. (confex.com)
  • Lymphoma is the second most common primary malignancy occurring in the head and neck. (medscape.com)
  • In the past, the rarity of non-B-cell malignancies and their similar morphologic findings, coupled with the unavailability of cell markers, made it impossible to establish definitive classifications of subtypes of non-B-cell NHL. (medscape.com)
  • It consists of the following subtypes: t(9;22)-BCR/ ABL t(v;11q23)-MLL rearrangement t(1;19)-E2A/PBX1 t(12;21)-ETV/ CBFα t(17;19)-E2A-HLF One interesting model of precursor B ALL shows aberrant function of a single gene, namely Pax5, as capable to change phenotype of B cells toward precursor cells. (wikipedia.org)
  • PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. (ucdenver.edu)
  • Additionally,Leukemia is diagnosed 10 times more often in adults than children.New cases of leukemia, lymphoma and myeloma are expected to account for 10 percent of the estimated 1,762,450 new cancer cases diagnosed in the US in 2019. (medgadget.com)
  • The study was performed in 423 younger adults with Philadelphia chromosome-negative ALL in first remission (265 B-cell precursor [BCP] and 158 T-cell ALL), with cumulative incidence of relapse (CIR) as the primary end point. (unige.ch)
  • Results from the analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with a consistent safety profile observed since the two-year analysis. (gilead.com)
  • In adults, B-cell precursor ALL is the most common form, accounting for 75% of cases. (gilead.com)
  • Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). (nih.gov)
  • The WHO modification of the REAL classification of NHL is based on morphology and cell lineage. (medscape.com)
  • In the absence of unequivocal proof of the exact lineage of NK-cell lymphoma, many investigators prefer to use the term NK/T-cell lymphoma (NKTCL) when classifying this condition. (medscape.com)
  • This study aimed to explore the associations between MTHFR or TS genetic polymorphisms and susceptibility to acute lymphocytic leukemia (ALL) in children. (medscimonit.com)
  • For examples include acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphomas and multiple myeloma. (medgadget.com)
  • Hematologic Malignancie market report is segmented on the basis of type, therapy and by regional & country level.Based upontype, Hematologic Malignancie market is classified intoLeukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Lymphoma,Multiple Myeloma and Others. (medgadget.com)
  • researchers are investigating Celyad's new CAR T therapy CYAD-01 in the treatment of acute myeloid leukemia (AML). (pharmacytimes.com)
  • Secondary Objectives: To evaluate the effect of the Fludarabine-(etoposide, doxorubicin, vincristine, prednisone, cyclophosphamide) EPOCH regimen on host T cell depletion and myeloid depletion prior to allogeneic SCT. (drugpatentwatch.com)
  • See also Pediatric Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia (AML) . (medscape.com)
  • Therapy-related acute myeloid leukemia (t-AML) characterized by the t(9;11)(p22;q23) translocation is one of the most frequent secondary malignancies. (uni-luebeck.de)
  • It has been approved in Europe to treat myelodysplastic syndromes, myeloid leukemia acute, and myelomonocytic leukemia chronic. (pharmakb.com)
  • This classification divides NHL into two groups: those of B-cell origin and those of T-cell/natural killer (NK)-cell origin. (medscape.com)
  • The unavailability of this information is demonstrated in previous classification systems, including the Lukes-Collins, Kiel, and Working Formulation systems, which did not identify subclasses of NK/T-cell malignancies. (medscape.com)
  • Advances in tumor cell biology have led to the ability to subclassify NHL via the World Health Organization (WHO) classification of lymphomas (see below). (medscape.com)
  • MNKPL is classified as mixed phenotype acute leukemia, and not otherwise specified rare types (MPAL NOS rare types) in WHO classification. (confex.com)
  • The Working Formulation, originally proposed in 1982, classified and grouped lymphomas by morphology and clinical behavior (ie, low, intermediate, or high grade) with 10 subgroups labeled A to J.{Ref 1} In 1994, the Revised European-American Lymphoma (REAL) classification attempted to apply immunophenotypic and genetic features in identifying distinct clinicopathologic NHL entities. (medscape.com)
  • The old classification system for lymphomas was discarded for a simpler model. (bvsalud.org)
  • These aberrant lymphoblasts proliferate, reducing the number of the normal marrow elements that produce other blood cell lines (red blood cells, platelets, and neutrophils). (medscape.com)
  • Continuous efforts have been made in Japan to investigate the role of hematopoietic stem cell transplantation (HSCT) for infants with KMT2A-r ALL, but improvement in outcome was modest. (nih.gov)
  • Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. (ucdenver.edu)
  • ZUMA-3 is an ongoing international multicenter (US, Canada, Europe), single arm, open label, registrational Phase 1/2 study of Tecartus in adult patients (≥18 years old) with ALL whose disease is refractory to or has relapsed following standard systemic therapy or hematopoietic stem cell transplantation. (gilead.com)
  • Vitamin D and bone minerals status in the long term survivors of childhood acute lymphoblastic leuke. (ac.ir)
  • It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. (lookformedical.com)
  • Methods: The Leukemia and Lymphoma Committee of the Japanese Society of Pediatric Hematology and Oncology (JSPHO) sent out questionnaires to 110 JSPHO affiliated hospitals and collected cases of MNPKL diagnosed during the period 2000-2013. (confex.com)
  • The National Cancer Institute's Working Formulation, originally proposed in 1982, classified and grouped lymphomas by morphology and clinical behavior (ie, low, intermediate, or high grade) with 10 subgroups labeled A to J. (medscape.com)
  • [ 3 ] Previous terms for NK-cell malignancies and other forms of non-B-cell NHL included lethal midline granuloma, angiocentric lymphoma, malignant granuloma, malignant midline reticulosis, and polymorphic reticulosis. (medscape.com)
  • These data indicate a potential for SERT as a novel anti-tumor target for amphetamine analogs, while evidence is presented that the seemingly more promising antidepressants are likely impacting malignant B cells independently of the transporter itself. (erowid.org)
  • Malignant transformation and uncontrolled proliferation of an abnormally differentiated, long-lived hematopoietic progenitor cell results in a high circulating number of blasts, replacement of normal marrow by malignant cells, and the potential for leukemic infiltration of the central nervous system (CNS) and testes. (msdmanuals.com)
  • Malignant transformation usually occurs at the pluripotent stem cell level, although it sometimes involves a committed stem cell with more limited capacity for self-renewal. (msdmanuals.com)
  • Abnormal proliferation, clonal expansion, aberrant differentiation, and diminished apoptosis (programmed cell death) lead to replacement of normal blood elements with malignant cells. (msdmanuals.com)
  • abstract = "IKAROS, encoded by the IKZF1 gene, is a DNA-binding protein that functions as a tumor suppressor in T cell acute lymphoblastic leukemia (T-ALL). (psu.edu)
  • A higher specific hazard of relapse was independently associated with postinduction MRD level ≥10(-4) and unfavorable genetic characteristics (ie, MLL gene rearrangement or focal IKZF1 gene deletion in BCP-ALL and no NOTCH1/FBXW7 mutation and/or N/K-RAS mutation and/or PTEN gene alteration in T-cell ALL). (unige.ch)
  • At $475,000, Novartis' Kymriah (tisagenlecleucel) is approved by FDA for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that's refractory or in second or later relapse. (managedhealthcareexecutive.com)
  • Relapse risk following truncation of PEG-asparaginase in childhood acute lymphoblastic leukemia. (cancercentrum.se)
  • ÓG, Vaitkeviciene G, Lepik K, Forslund A, Heyman M, Harila-Saari A. Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols. (cancercentrum.se)
  • Arm I (closed to accrual as of 4/2006): Patients receive same induction, consolidation, and interim maintenance therapy schedule as localized lymphoblastic lymphoma patients. (knowcancer.com)
  • Maintenance (84 day course): Patients receive same therapy as localized lymphoblastic lymphoma patients, except methotrexate IT is administered on day 0 and 28 (for first 4 courses). (knowcancer.com)
  • With intensified pediatric-like therapy and genetic disease dissection, the field of adult acute lymphoblastic leukemia (ALL) has evolved recently. (unige.ch)
  • In this new context, we aimed to reassess the value of conventional risk factors with regard to new genetic alterations and early response to therapy, as assessed by immunoglobulin/T-cell receptor minimal residual disease (MRD) levels. (unige.ch)
  • SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus ® (brexucabtagene autoleucel). (gilead.com)
  • In this installment, Drs. Abutalib, Hashmi, and Porter explore the chimeric antigen receptor (CAR) T-cell gene therapy, focusing on managing the well-recognized adverse events specific to the U.S. Food and Drug Administration (FDA)-approved anti-CD19 CAR T-cell therapies (Table 1). (ascopost.com)
  • Recently, the FDA and European Medical Association approved two anti-CD19 CAR T-cell therapy products: tisagenlecleucel and axicabtagene ciloleucel. (ascopost.com)
  • Founder and Co-Editor, Advances in Cell and Gene Therapy. (ascopost.com)
  • Not all CAR T-cell therapy products are created equal (tisagenlecleucel ≠ axicabtagene ciloleucel)! (ascopost.com)
  • Approximately what proportion of patients develop infection(s) after the first month of CAR T-cell therapy platform (lymphodepleting therapy plus anti-CD 19 CAR T-cell infusion) despite being on appropriate antimicrobial prophylaxis? (ascopost.com)
  • An alternative approach to engage T cells for cancer therapy are antibodies, which are bispecific for a surface target antigen on cancer cells, and for CD3 on T cells. (aacrjournals.org)
  • DNA polymerase gamma variants and hepatotoxicity during maintenance therapy of childhood acute lymphoblastic leukemia: is there a causal relationship? (regionh.dk)
  • CAR T-cell therapy and other immunotherapies may cure patients who have endured multiple rounds of treatment. (managedhealthcareexecutive.com)
  • The drug is used in the therapy of acute leukemia. (lookformedical.com)
  • check the tag ADOLESCENCE HN - 2008 BX - Nutrition in Adolescence FX - Adolescent Nutrition Physiology MH - Peritoneal Stomata UI - D054048 MN - A01.047.025.600.700 MN - A10.810 MS - Natural openings in the subdiaphragmatic lymphatic plexus in the PERITONEUM, delimited by adjacent mesothelial cells. (bvsalud.org)
  • C. Severe neurologic toxicities were observed in 30% to 40% of pediatric and young adult patients with relapsed/refractory B-cell ALL and adult patients with relapsed/refractory large B-cell lymphomas. (ascopost.com)
  • Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. (nih.gov)
  • however, Kymriah holds an additional indication to treat B-cell precursor acute lymphoblastic leukemia in certain pediatric and young adult patients. (pharmacytimes.com)
  • The continued durable response and significant improvement in survival indicated by these new data can potentially establish a new standard of care for adult patients living with this aggressive form of leukemia. (gilead.com)
  • B. Neurotoxicity was observed in 50% of adult patients with large B-cell lymphomas. (ascopost.com)
  • To determine the treatment-related morbidity and mortality of allogeneic stem cell transplantation using a non-myeloablative conditioning regimen in multiple myeloma. (drugpatentwatch.com)
  • The American Cancer Society estimates that in the United States in 2023 there will be over 6500 new cases of acute lymphoblastic leukemia (ALL) and almost 1400 deaths will have occurred. (msdmanuals.com)
  • Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. (ucdenver.edu)
  • 1 Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan. (nih.gov)
  • 2016. Sulforaphane modulates telomerase activity via epigenetic regulation in prostate cancer cell lines. . (oregonstate.edu)
  • The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells. (oregonstate.edu)
  • Effects of sulforaphane and 3,3'-diindolylmethane on genome-wide promoter methylation in normal prostate epithelial cells and prostate cancer cells. (oregonstate.edu)
  • According to Leukemia Research Foundation, in2019, every three minutes, someone is diagnosed with blood cancer more than 175,000 new cases are expected in the United States. (medgadget.com)
  • ALL is the most common type of cancer and leukemia in children in the United States. (medscape.com)
  • Jodi Fisher Horowitz Professor in Leukemia Care Excellence, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania, Philadelphia. (ascopost.com)
  • There is increasing evidence that T cells are able to control tumor growth and survival in cancer patients, both in early and late stages of the disease. (aacrjournals.org)
  • However, tumor-specific T-cell responses are difficult to mount and sustain in cancer patients, and are limited by numerous immune escape mechanisms of tumor cells selected during immunoediting. (aacrjournals.org)
  • These are capable of connecting any kind of cytotoxic T cell to a cancer cell, independently of T-cell receptor specificity, costimulation, or peptide antigen presentation. (aacrjournals.org)
  • The concept of using such bispecific antibodies to engage cytotoxic T cells for cancer cell lysis was shown by Staerz and colleagues ( 1 ). (aacrjournals.org)
  • Pioneering work by Kufer and colleagues ( 6 ) showed that CD3/target antigen-bispecific antibodies of this particular design had an exceptionally high potency, and could likewise engage CD8 + and CD4 + T cells for redirected lysis of cancer cells at very low effector to target (E:T) ratios. (aacrjournals.org)
  • Wnt-5a has since been suggested as a candidate ligand for ROR1, and ROR1 has been implicated to function as a pseudokinase, promoting proliferation and resistance to apoptosis in cancer cells through interaction with Wnt-5a, and TCL1-co-activation of AKT. (peprotech.com)
  • Acute lymphoblastic leukemia (ALL) is a highly aggressive pediatric cancer that can affect both B cells and T cells. (lu.se)
  • We observed that all the venetoclax-resistant T-ALL cell lines displayed non-universal changes in the expression of BCL2 family members and cancer stem cell markers, along with specific enrichment of cytokine signaling pathways. (lu.se)
  • It is the most common cancer in children and accounts for the vast majority of all childhood leukemias. (lookformedical.com)
  • Allogeneic stem cell transplantation (SCT) results in a high percentage of complete remissions, but it can be associated with significant treatment-related mortality, which has been primarily attributed to conventional myeloablative transplant regimens. (drugpatentwatch.com)
  • The study aims to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL). (rochester.edu)
  • CT scan of a patient with a natural killer (NK)/T-cell lymphoma of the right nasal cavity and maxillary sinus. (medscape.com)